ReviewCNS & neurological disorders drug targets2008
Role of secretory phospholipase a(2) in CNS inflammation: implications in traumatic spinal cord injury.
Review in CNS & neurological disorders drug targets, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 36 citations in OpenAlex.
- Human Group IIA Phospholipase AMolecules (Basel, Switzerland) · 2021Review
- Early upregulation of cytosolic phospholipase AJournal of neuroinflammation · 2021Article
- Laminin-coated multifilament entubulation, combined with Schwann cells and glial cell line-derived neurotrophic factor, promotes unidirectional axonal regeneration in a rat model of thoracic spinal cord hemisection.Neural regeneration research · 2021Article
- Changes in transcriptome profiling during the acute/subacute phases of contusional spinal cord injury in rats.Annals of translational medicine · 2020Article
- Article
- 3D MALDI mass spectrometry imaging reveals specific localization of long-chain acylcarnitines within a 10-day time window of spinal cord injury.Scientific reports · 2018Article
- Matrix-Assisted Laser Desorption Ionization Mapping of Lysophosphatidic Acid Changes after Traumatic Brain Injury and the Relationship to Cellular Pathology.The American journal of pathology · 2018Article
- Minocycline targets multiple secondary injury mechanisms in traumatic spinal cord injury.Neural regeneration research · 2017Review
- Biochemical, cell biological, pathological, and therapeutic aspects of Krabbe's disease.Journal of neuroscience research · 2016Review
- Distribution of secretory phospholipase A2 XIIA in the brain and its role in lipid metabolism and cognition.Molecular neurobiology · 2014Article
- Cytosolic phospholipase A2 protein as a novel therapeutic target for spinal cord injury.Annals of neurology · 2014Article
- High-resolution intravital imaging reveals that blood-derived macrophages but not resident microglia facilitate secondary axonal dieback in traumatic spinal cord injury.Experimental neurology · 2014Article
- The proteome of the differentiating mesencephalic progenitor cell line CSM14.1 in vitro.BioMed research international · 2014Article
- Neuroprotection and its molecular mechanism following spinal cord injury.Neural regeneration research · 2012Review
- Stability, disposition, and penetration of catalytic antioxidants Mn-porphyrin and Mn-salen and of methylprednisolone in spinal cord injury.Central nervous system agents in medicinal chemistry · 2012Article
- Article
- Phospholipases A2 and neural membrane dynamics: implications for Alzheimer's disease.Journal of neurochemistry · 2011Review
- Phospholipases A2 and inflammatory responses in the central nervous system.Neuromolecular medicine · 2010Review
- Regeneration of spinal cord with cell and gene therapy.Orthopaedic surgery · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Secretory phospholipases A(2) (sPLA(2)s) are a subfamily of lipolytic enzymes which hydrolyze the acyl bond at the sn-2 position of glycerophospholipids to produce free fatty acids and lysophospholipids. These products are precursors of bioactive eicosanoids and platelet-activating factor (PAF). The hydrolysis of membrane phospholipids by PLA(2) is a rate-limiting step for generation of eicosanoids and PAF. To date, more than 10 isozymes of sPLA(2) have been found in the mammalian central nervous system (CNS). Under physiological conditions, sPLA(2)s are involved in diverse cellular responses, including host defense, phospholipid digestion and metabolism. However, under pathological situations, increased sPLA(2) activity and excessive production of free fatty acids and their metabolites may lead to inflammation, loss of membrane integrity, oxidative stress, and subsequent tissue injury. Emerging evidence suggests that sPLA(2) plays a role in the secondary injury process after traumatic or ischemic injuries in the brain and spinal cord. Importantly, sPLA(2) may act as a convergence molecule that mediates multiple key mechanisms involved in the secondary injury since it can be induced by multiple toxic factors such as inflammatory cytokines, free radicals, and excitatory amino acids, and its activation and metabolites can exacerbate the secondary injury. Blocking sPLA(2) action may represent a novel and efficient strategy to block multiple injury pathways associated with the CNS secondary injury. This review outlines the current knowledge of sPLA(2) in the CNS with emphasis placed on the possible roles of sPLA(2) in mediating CNS injuries, particularly the traumatic and ischemic injuries in the brain and spinal cord.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.